This site is intended for healthcare professionals
News

Alnylam submits MAA to the European Medicines Agency for investigational vutrisiran.

Read time: 1 mins
Last updated:15th Sep 2021
Published:15th Sep 2021
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for vutrisiran, an investigational RNAi therapeutic for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with polyneuropathy.
Condition: TTR Familial Amyloid Polyneuropathy
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest